Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
A 16-week, Randomized, Placebo-controlled, Double Blind, and Parallel Group Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease
The objective of the Biopsy trial is to investigate the effect of roflumilast 500 µg tablets
once daily versus placebo on inflammation parameters in bronchial biopsy tissue specimen and
additional in sputum and blood serum. Also data on safety status will be obtained.
Patients to be included required to have moderate to severe COPD associated with chronic
bronchitis. The total duration of this randomized, multicentre, phase III trial is 24 weeks
maximum.
This was a multicenter, double-blind, randomized, parallel group, phase 3 study. Patients
included had a history of COPD (GOLD stage II-III, in Germany stage II only) with chronic
productive cough.
There were 2 parallel treatment arms (placebo and roflumilast 500 μg once daily). A 1 to 1
randomization scheme was used, that is, patients were allocated to roflumilast 500 μg or
placebo in equal proportions. Randomization was stratified by concomitant LABA use.
The total duration of this study was 24 weeks maximum per patient. The study consisted of the
following periods:
- Single-blind placebo run-in period (6 weeks) with visits at Week -6 (visit 0 [V0]), Week
-2 (V1), and Week 0 (V2, randomization visit), during which all patients received
placebo.
- Double-blind treatment period (16 weeks) during which patients received either
roflumilast or matching placebo with visits at Week 6 (V4), Week 14 (V5), and Week 16
(V6).
An additional visit (V3) within 2 weeks after bronchoscopy/bronchial biopsy was performed
purely as a safety visit. The exact timing of this safety visit was to be determined by the
investigator. Safety follow-up. All AEs were followed up to 30 days after the double-blind
treatment period. An additional safety visit, V7, was scheduled within 2 weeks after the
second bronchoscopy. The exact timing of the safety visit was to be determined by the
investigator.
Patients were required not to take any food or drink overnight for at least 8 hours prior to
returning to the study center for each visit. Patients were also asked to avoid strenuous
exercise for 8 hours prior to each study visit and to avoid smoking for 4 hours prior to each
study visit.
For visits where patients did not undergo blood collections or biopsies, the fasting
requirement was only mandated if clinically indicated, per investigator judgment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|